$TLCC
Twinlab Consolidated Holdings Inc Stock $tlcc

$tlcc Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000175392623000492 Filed on April 24, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$4.879M	$9.023M	$13.25M
YoY Change	-66.29%	-31.91%	-31.91%
Cost Of Revenue	$4.105M	$6.811M	$8.822M
YoY Change	-61.67%	-22.8%	-28.52%
Gross Profit	$774.0K	$2.212M	$4.429M
YoY Change	-79.43%	-50.06%	-37.78%
Gross Profit Margin	15.86%	24.52%	33.42%
Selling, General & Admin	$2.511M	$2.935M	$3.992M
YoY Change	-37.3%	-26.48%	-12.21%
% of Gross Profit	324.42%	132.69%	90.13%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$12.00K	$12.00K	$40.00K
YoY Change	-7.69%	-70.0%	-59.6%
% of Gross Profit	1.55%	0.54%	0.9%
Operating Expenses	$2.511M	$2.935M	$3.992M
YoY Change	-37.3%	-26.48%	-12.21%
Operating Profit	-$1.737M	-$723.0K	$437.0K
YoY Change	614.81%	-265.45%	-83.0%
Interest Expense	$2.205M	$2.117M	$1.837M
YoY Change	11.59%	15.24%	-15.31%
% of Operating Profit			420.37%
Other Income/Expense, Net	-$2.248M	-$2.087M	-$161.0K
YoY Change	13.77%	1196.27%	-92.64%
Pretax Income	-$3.985M	-$2.810M	$276.0K
YoY Change	79.59%	-1118.12%	-27.94%
Income Tax	$6.000K	$0.00	$0.00
% Of Pretax Income			0.0%
Net Earnings	-$3.991M	-$2.810M	$276.0K
YoY Change	79.86%	-1118.12%	-27.94%
Net Earnings / Revenue	-81.8%	-31.14%	2.08%
Basic Earnings Per Share	-$0.02	-$0.01	$0.00
Diluted Earnings Per Share	-$0.02	-$0.01	$0.00
COMMON SHARES
Basic Shares Outstanding	259.1M shares	259.1M shares	259.1M shares
Diluted Shares Outstanding	259.1M shares	259.1M shares	259.1M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$142.0K	$101.0K	$1.761M
YoY Change	0.0%	-94.26%	-45.58%
Cash & Equivalents	$142.0K	$101.0K	$1.761M
Short-Term Investments
Other Short-Term Assets	$934.0K	$1.463M	$714.0K
YoY Change	65.31%	104.9%	-74.84%
Inventory	$5.482M	$7.461M	$7.618M
Prepaid Expenses
Receivables	$2.828M	$2.393M	$6.494M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$9.386M	$11.42M	$16.59M
YoY Change	-42.01%	-31.16%	-34.38%
LONG-TERM ASSETS
Property, Plant & Equipment	$100.0K	$117.0K	$135.0K
YoY Change	-53.49%	-13.33%	125.0%
Goodwill
YoY Change
Intangibles	$120.0K	$120.0K	$547.0K
YoY Change	-76.83%	-78.06%	-82.68%
Long-Term Investments
YoY Change
Other Assets	$1.258M	$1.301M	$1.301M
YoY Change	-3.31%	0.0%	74.87%
Total Long-Term Assets	$4.422M	$5.471M	$7.226M
YoY Change	-37.2%	-24.29%	-60.27%
TOTAL ASSETS
Total Short-Term Assets	$9.386M	$11.42M	$16.59M
Total Long-Term Assets	$4.422M	$5.471M	$7.226M
Total Assets	$13.81M	$16.89M	$23.81M
YoY Change	-40.55%	-29.08%	-45.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.282M	$4.964M	$2.407M
YoY Change	15.63%	106.23%	-67.02%
Accrued Expenses	$39.85M	$37.92M	$32.82M
YoY Change	18.07%	15.51%	23.14%
Deferred Revenue	$2.125M	$2.019M	$1.986M
YoY Change	2.36%	1.66%	-59.92%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$95.65M	$96.37M	$98.49M
YoY Change	-1.64%	-2.15%	-1.59%
Total Short-Term Liabilities	$142.9M	$141.3M	$135.7M
YoY Change	3.83%	4.1%	-2.36%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$3.022M	$3.741M	$4.919M
YoY Change	-34.76%	-23.95%	-5.71%
Total Long-Term Liabilities	$3.022M	$3.741M	$4.919M
YoY Change	-34.76%	-23.95%	-21.21%
TOTAL LIABILITIES
Total Short-Term Liabilities	$142.9M	$141.3M	$135.7M
Total Long-Term Liabilities	$3.022M	$3.741M	$4.919M
Total Liabilities	$145.9M	$145.0M	$140.6M
YoY Change	2.57%	3.12%	-3.17%
SHAREHOLDERS EQUITY
Retained Earnings	-$363.2M	-$359.2M	-$347.9M
YoY Change	3.74%	3.25%	4.52%
Common Stock	$231.6M	$231.6M	$231.6M
YoY Change	0.0%	0.0%	58692.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$500.0K	$500.0K	$500.0K
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares	134.8M shares	134.8M shares	134.8M shares
Shareholders Equity	-$132.1M	-$128.1M	-$116.8M
YoY Change
Total Liabilities & Shareholders Equity	$13.81M	$16.89M	$23.81M
YoY Change	-40.55%	-29.08%	-45.22%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$3.991M	-$2.810M	$276.0K
YoY Change	79.86%	-1118.12%	-27.94%
Depreciation, Depletion And Amortization	$12.00K	$12.00K	$40.00K
YoY Change	-7.69%	-70.0%	-59.6%
Cash From Operating Activities	$766.0K	$243.0K	-$4.621M
YoY Change	-382.66%	-105.26%	510.44%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$6.000K
YoY Change	-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$6.000K
YoY Change	-100.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-725.0K	-1.010M	2.757M
YoY Change	-42.23%	-136.63%	-22.75%
NET CHANGE
Cash From Operating Activities	766.0K	$243.0K	-$4.621M
Cash From Investing Activities	0.000	0.000	-6.000K
Cash From Financing Activities	-725.0K	-1.010M	2.757M
Net Change In Cash	41.00K	-$767.0K	-$4.621M
YoY Change	-102.53%	-83.4%	-264.33%
FREE CASH FLOW
Cash From Operating Activities	$766.0K	$243.0K	-$4.621M
Capital Expenditures	$0.00	$0.00	$6.000K
Free Cash Flow	$766.0K	$243.0K	-$4.627M
YoY Change	-310.44%	-105.25%	511.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	758000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	11418000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	15138000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	117000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	188000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3933000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4165000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	120000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	120000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1301000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1301000	usd
CY2023Q1	us-gaap	Assets Assets	16889000	usd
CY2022Q4	us-gaap	Assets Assets	20912000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4964000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6621000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1178000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1159000	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3832000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3708000	usd
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001590695
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	000-55181
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Twinlab Consolidated Holdings, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-3951742
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	4800 T-Rex Avenue, Suite 225
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Boca Raton
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33431
CY2023Q1	dei	City Area Code CityAreaCode	561
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	443-4301
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	259092833	shares
CY2023Q1	us-gaap	Cash Cash	101000	usd
CY2022Q4	us-gaap	Cash Cash	868000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2393000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4105000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	7461000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	9407000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1463000	usd
CY2023Q1	us-gaap	Interest Payable Current InterestPayableCurrent	34924000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	33316000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	96371000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	97381000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	141269000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	142185000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3741000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4038000	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3741000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4038000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	145010000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	146223000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	393898884	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	393898884	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	394000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	394000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	231249000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	231249000	usd
CY2023Q1	us-gaap	Common Stock Share Subscribed But Unissued Subscriptions Receivable CommonStockShareSubscribedButUnissuedSubscriptionsReceivable	30000	usd
CY2022Q4	us-gaap	Common Stock Share Subscribed But Unissued Subscriptions Receivable CommonStockShareSubscribedButUnissuedSubscriptionsReceivable	30000	usd
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	134806051	shares
CY2023Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	134806051	shares
CY2023Q1	us-gaap	Treasury Stock Value TreasuryStockValue	500000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	500000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-359234000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-356424000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-128121000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-125311000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16889000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20912000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9023000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	13251000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6811000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8822000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	2212000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	4429000	usd
CY2023Q1	us-gaap	Selling Expense SellingExpense	439000	usd
CY2022Q1	us-gaap	Selling Expense SellingExpense	924000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2496000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3068000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-723000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	437000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	2117000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	1837000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	30000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1676000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2087000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-161000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2810000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	276000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2810000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	276000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	259092833	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	259092833	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	259092833	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	259092833	shares
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-117089000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-116813000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-125311000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2810000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-128121000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2810000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	276000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	40000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	232000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	237000	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	-126000	usd
CY2022Q1	us-gaap	Inventory Write Down InventoryWriteDown	-164000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-165000	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	240000	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1674000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-58000	usd
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1876000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-147000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2072000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1640000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	705000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-331000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1657000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3640000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-278000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-246000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1734000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1472000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	243000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4621000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6000	usd
CY2023Q1	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-1010000	usd
CY2022Q1	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	2757000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-767000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1870000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	868000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3631000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	101000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1761000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	509000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	237000	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-weight: bold;">Note </span><span style="font-family: 'Times New Roman'; font-weight: bold;"><span style="border-left: none; border-right: none;">1</span></span> <span style="font-family: 'Times New Roman';">–</span><span style="font-family: 'Times New Roman'; font-weight: bold;"> Nature of Business </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Nature of Business</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt; text-align: justify; font-size: 10pt;"><span style="font-family: 'Times New Roman';">Twinlab Consolidated Holdings, Inc. (the “Company”, “Twinlab,” “we,” “our” and “us”) was incorporated on </span><span style="font-family: 'Times New Roman';">October 24, 2013 </span><span style="font-family: 'Times New Roman';">under the laws of the State of Nevada as Mirror Me, Inc. On </span><span style="font-family: 'Times New Roman';">August 7, 2014, </span><span style="font-family: 'Times New Roman';">we amended our articles of incorporation and changed our name to Twinlab Consolidated Holdings, Inc.</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt; text-align: justify; font-size: 10pt;"><span style="font-family: 'Times New Roman';">We are an integrated marketer, distributor, and retailer of branded nutritional supplements and other natural products sold to and through domestic health and natural food stores, mass market retailers, specialty store retailers, on-line retailers, and websites. Internationally, we market and distribute branded nutritional supplements and other natural products to and through health and natural product distributors and retailers.</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt; text-align: justify; font-size: 10pt;"><span style="font-family: 'Times New Roman';">Our products include vitamins, minerals, specialty supplements and sports nutrition products sold under the Twinlab<span style="color: #000000; font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 36px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">®</span> brand name, a market leader in the healthy aging and beauty from within categories sold under the Reserveage Nutrition and ResVitale® brand names; diet and energy products sold under the Metabolife<span style="color: #000000; font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 36px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">®</span> brand name; and a full line of herbal teas sold under the Alvita<span style="color: #000000; font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 36px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">®</span> brand name. To accommodate consumer preferences, our products come in various formulations and delivery forms, including capsules, tablets, softgels, chewables, liquids, sprays and powders. These products are sold primarily through health and natural food stores and on-line retailers, supermarkets, and mass-market retailers.</span><span style="font-family: 'Times New Roman';"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt; text-align: justify; font-size: 10pt;"><span style="font-family: 'Times New Roman';">We also perform services between private label distributors and contract manufacturers under the NutraScience Labs (“NSL”) brand name. NSL facilitates the production of new supplements to market and reformulates existing products to include scientifically-backed ingredients. We provide our customers with numerous production services, including manufacturing, testing, label and packaging design, order fulfillment, and regulatory compliance.</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt; text-align: justify; font-size: 10pt;"><span style="font-family: 'Times New Roman';">NSL facilitates the contract manufacture of a variety of high-quality vitamin and supplement products, including but </span><span style="font-family: 'Times New Roman';">not</span><span style="font-family: 'Times New Roman';"> limited to, immune support supplements, cognitive support products, prebiotics and probiotics, supplements for weight management, and sports nutrition supplements. Our role in the production of these products is to help our customers manufacture or reformulate dietary supplements for sale and distribution. We do this by working with contract manufacturers to build scientifically backed formulas for resale to our end customers. We also simplify the production process by providing quality control checks, storing inventory on site, labeling and designing finished products, and drop shipping finished products ready for sale to our end customers. We do </span><span style="font-family: 'Times New Roman';">not</span><span style="font-family: 'Times New Roman';"> market these private label products, but rather sell the products to the customer, who is then responsible for the marketing, distribution, and sale to retailers or to their end customers. </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Going Concern</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt; text-align: justify; font-size: 10pt;"><span style="font-family: 'Times New Roman';">The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which assumes continuity of operations and realization of assets and liabilities in the ordinary course of business. As of </span><span style="font-family: 'Times New Roman';">March 31, 2023, </span><span style="font-family: 'Times New Roman';">we had an accumulated def<span>icit of $</span></span><span><span style="font-family: 'Times New Roman';">359,234</span></span><span style="font-family: 'Times New Roman';">. Historical losses are primarily attributable to lower than planned sales resulting from low fill rates on demand due to limitations of our working capital, delayed product introductions and postponed marketing activities, merger-related and other restructuring costs, and interest and refinancing charges associated with our debt refinancing. Losses have been funded primarily through debt.</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt; text-align: justify; font-size: 10pt;"><span style="font-family: 'Times New Roman';">Because of our history of operating losses and significant interest expense on our debt, we have a working capital deficiency of $</span><span style="font-family: 'Times New Roman';"><span style="border-left: none; border-right: none;">129,851</span></span><span style="font-family: 'Times New Roman';"> as of <span style="color: #000000; font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 36px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">March 31, 2023</span></span><span style="font-family: 'Times New Roman';">. </span><span style="font-family: 'Times New Roman';">We also have $</span><span style="font-family: 'Times New Roman';">96,371</span><span style="font-family: 'Times New Roman';"> of debt, presented in current liabilities. These continuing conditions, among others, raise substantial doubt about our ability to continue as a going concern.</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt; text-align: justify; font-size: 10pt;"><span style="font-family: 'Times New Roman';">Management is addressing operating issues through the following actions: focusing on growing the core business and brands; continuing emphasis on major customers and key products; reducing operating costs that include significant workforce and salary expense reduction and continuing to negotiate lower prices from major suppliers. </span><span style="font-family: 'Times New Roman';">We will need to raise additional capital through debt, equity or sale of assets during the current year</span><span style="font-family: 'Times New Roman';">. If additional funding is required, there can be </span><span style="font-family: 'Times New Roman';">no</span><span style="font-family: 'Times New Roman';"> assurance that sources of funding will be available when needed on acceptable terms or at all. </span></p>
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-359234000	usd
CY2023Q1	tlcc	Working Capital Deficiency WorkingCapitalDeficiency	129851000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	96371000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-style: italic; font-size: 10pt;">Use of Estimates</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt; text-align: justify; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Actual results could differ from those estimates. Significant management estimates include those with respect to returns and allowances, allowance for doubtful accounts receivable, allowance for credit losses, reserves for inventory obsolescence, the recoverability of long-lived assets, intangibles and goodwill.</span></p>
CY2022Q4	us-gaap	Contract With Customer Asset Accumulated Allowance For Credit Loss ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss	1546000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	534000	usd
CY2023Q1	tlcc	Contract With Customer Liability Customer Deposits Current ContractWithCustomerLiabilityCustomerDepositsCurrent	1976000	usd
CY2022Q4	tlcc	Contract With Customer Liability Customer Deposits Current ContractWithCustomerLiabilityCustomerDepositsCurrent	1856000	usd
CY2023Q1	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	43000	usd
CY2022Q4	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	45000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2019000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1901000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9023000	usd
CY2023Q1	us-gaap	Contract With Customer Asset Accumulated Allowance For Credit Loss ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss	1381000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	431000	usd
CY2023Q1	tlcc	Accounts Receivable Allowance For Expected Credit Loss Current AccountsReceivableAllowanceForExpectedCreditLossCurrent	41000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2810000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	276000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	259092833	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	259092833	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	259092833	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	259092833	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-style: italic; font-size: 10pt;">Significant Concentration of Credit Risk</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt; text-align: justify; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-family: 'times new roman', times; font-size: 10pt;"><span>Sales to our top <span style="border-left: none; border-right: none;">three</span> customers aggregated to approximately </span><span>23</span>% and <span>31</span>% of total sales for the <span style="border-left: none; border-right: none;"><span style="border-left: none; border-right: none;"><span style="border-right: none; border-left: none;">three months ended March 31, 2023</span></span></span> and 2022,<span> respectively.</span> Sales to <span><span style="border-left: none; border-right: none;">one</span></span> of those customers were approximately <span>10</span>% and <span>12</span>% of total sales for the <span style="border-left: none; border-right: none;"><span style="border-right: none; border-left: none;"><span style="border-left: none; border-right: none;">three months ended March 31, 2023</span></span></span> and <span style="border-left: none; border-right: none;">2022</span>,<span> respectively. </span>Accounts receivable from these <span><span style="border-left: none; border-right: none;">three</span></span> customers were approximately <span>34</span>% and <span>28</span>% <span style="text-indent: 27pt;">of total accounts receivable as of </span><span style="text-indent: 27pt;">March 31, 2023 </span><span style="text-indent: 27pt;">and </span><span style="text-indent: 27pt;">December 31, 2022, </span><span style="text-indent: 27pt;">respectively.</span> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt; text-align: justify; font-size: 10pt; font-family: 'Times New Roman';"><br/></p> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt; text-align: justify; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-family: 'times new roman', times; font-size: 10pt;"><span style="text-indent: 27pt;">A <span style="border-left: none; border-right: none;">single</span> customer represents </span><span style="text-indent: 27pt;">14</span><span style="text-indent: 27pt;">% and </span><span style="text-indent: 27pt;">2</span><span style="text-indent: 27pt;">% of total accounts receivable as of </span><span style="text-indent: 27pt;">March 31, 2023 </span><span style="text-indent: 27pt;">and </span><span style="text-indent: 27pt;">December 31, 2022</span><span style="text-indent: 27pt;">, </span><span style="text-indent: 27pt;">respectively. This customer is a related party through a director who sits on both the Company’s board of directors and that of the customer.</span></span></p>
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	563000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	906000	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6995000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	8724000	usd
CY2023Q1	us-gaap	Inventory Gross InventoryGross	7558000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	9630000	usd
CY2023Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	97000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	223000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	7461000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	9407000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	251000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	310000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	134000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	122000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	117000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	188000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	12000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	11000	usd
CY2023Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	120000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	120000	usd
CY2023Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	10882000	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	10882000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10762000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10762000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	120000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	120000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	29000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	96371000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	97381000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	96371000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	97381000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4500000	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2023Q1	tlcc	Class Of Warrant Or Right Granted During Period Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightGrantedDuringPeriodNumberOfSecuritiesCalledByWarrantsOrRights	0	shares
CY2023Q1	tlcc	Class Of Warrant Or Right Granted During Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightGrantedDuringPeriodExercisePriceOfWarrantsOrRights	0
CY2023Q1	tlcc	Class Of Warrant Or Right Cancelled During Period Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightCancelledDuringPeriodNumberOfSecuritiesCalledByWarrantsOrRights	0	shares
CY2023Q1	tlcc	Class Of Warrant Or Right Canceled During Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightCanceledDuringPeriodExercisePriceOfWarrantsOrRights	0
CY2023Q1	tlcc	Class Of Warrant Or Right Exercised During Period Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightExercisedDuringPeriodNumberOfSecuritiesCalledByWarrantsOrRights	0	shares
CY2023Q1	tlcc	Class Of Warrant Or Right Exercised During Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisedDuringPeriodExercisePriceOfWarrantsOrRights	0
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4500000	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2023Q1	us-gaap	Lease Cost LeaseCost	222000	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	209000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	49000	usd
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	93000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1154000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1523000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1566000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1150000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	306000	usd
CY2023Q1	tlcc	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	0	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5699000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	780000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4919000	usd
CY2023Q1	us-gaap	Sublease Income SubleaseIncome	162000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	380000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M12D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0825	pure
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	1528384	shares
CY2023Q1	us-gaap	Common Stock Share Subscribed But Unissued Subscriptions Receivable CommonStockShareSubscribedButUnissuedSubscriptionsReceivable	30000	usd
CY2023Q1	tlcc	Subscription Receivable Annual Interest Rate SubscriptionReceivableAnnualInterestRate	0.05	pure

Files In Submission

Name	View Source	Status
0001753926-23-000492-index-headers.html	Edgar Link	pending
0001753926-23-000492-index.html	Edgar Link	pending
0001753926-23-000492.txt	Edgar Link	pending
0001753926-23-000492-xbrl.zip	Edgar Link	pending
ex311_1.htm	Edgar Link	pending
ex321_2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tlcc-20230331.htm	Edgar Link	pending
tlcc-20230331.xsd	Edgar Link	pending
tlcc-20230331_cal.xml	Edgar Link	unprocessable
tlcc-20230331_def.xml	Edgar Link	unprocessable
tlcc-20230331_lab.xml	Edgar Link	unprocessable
tlcc-20230331_pre.xml	Edgar Link	unprocessable
tlcc-20230331_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TLCC
Twinlab Consolidated Holdings Inc Stock $tlcc

2023 Q2 Form 10-Q Financial Statement

#000175392623000492 Filed on April 24, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TLCC Twinlab Consolidated Holdings Inc Stock $tlcc

2023 Q2 Form 10-Q Financial Statement

#000175392623000492 Filed on April 24, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TLCC
Twinlab Consolidated Holdings Inc Stock $tlcc